Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

NCT04799990 · clinicaltrials.gov ↗

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study is not recruiting and using secondary data sources only

Conditions

Psoriasis

Interventions

DRUG: Risankizumab
BIOLOGICAL: Comparator 1
DRUG: Comparator 2

Sponsor

AbbVie